Aequitas Presents Findings for Myocardial Perfusion Imaging at International Conference for Pharmacoeconomics and Outcomes Research; Research and Analysis Firm Shows Improved Health Outcomes When Imaging Technique is Utilized
Posted on: Friday, 20 May 2005, 09:00 CDT
Aequitas, a highly-regarded strategic healthcare advisory firm, presented the results of their investigation on the use of non-invasive myocardial perfusion imaging (MPI) for the detection of coronary artery disease (CAD) in asymptomatic patients with diabetes mellitus at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual International Meeting in Washington DC, May 15-18, 2005.
The presentations were entitled:
-- EARLY DETECTION OF CVD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
-- COST-EFFECTIVENESS OF DETECTION OF CAD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
CAD is a frequent comorbidity in patients with diabetes. Unfortunately, the expression of chest pain is physiologically altered in these patients and they may have CAD without clinical symptoms.
Medical claims-based analyses completed by Aequitas showed the rate of cardiovascular disease events in sixty 53-year old males who were observed for 24 months was 4.5-times greater in patients where MPI had not been used for the evaluation of CAD but current management standards were otherwise followed. However, in a matched population who underwent an MPI study, over 25% of asymptomatic patients demonstrated abnormal MPI findings. Of those who did not undergo MPI, 15% experienced cardiac events including myocardial infarction, dysrhythmias, and heart failure during the 24-month observation interval.
"Used to assess both myocardial perfusion and function, MPI represents a technique for early detection of CAD in a vulnerable, high risk population," states Frank Papatheofanis, MD, MPH, PhD, President and CEO of Aequitas. "The rising number of patients with diabetes will also reflect a rise in associated morbidity. The cost savings associated with preventing versus treating these comorbidities will be significant in the years to come."
About Aequitas
Aequitas is a leading independent research and analysis firm that specializes in the development of evidence-based product valuation for multiple stakeholders and provides solutions to support the development, management and marketing of new and existing technologies throughout the healthcare industry. For copies of the above abstracts or more information, please visit our Web site at www.aequitas.us.
Source: Business Wire
Related Articles
- Lipitor 80 Mg Reduced the Risk of Heart Attack and Stroke in Patients With Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
- Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients With Type 1 and Type 2 Diabetes
- Two-Thirds of Healthcare Professionals Polled Attribute Improved Patient Self-Management to the U.S. Diabetes Conversation Map(R) Program
- Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
- CERA Year-Long Extension Phase II Data Showed Sustained and Stable Control of Anemia Irrespective of Patients' Gender, Race, Age or Diabetic Status
- Noninvasive Diagnosis of Coronary Artery Disease in Patients With Diabetes By Dobutamine Stress Real-Time Myocardial Contrast Perfusion Imaging
- Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study
- Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects
- Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes: Early Treatment Diabetic Retinopathy Study Report No. 27
- Prediction of Infarct-Related Coronary Artery of Patients With Acute Inferior Myocardial Infarction By a Predischarge Exercise Test Index
 |
 |
User Comments (0)
RSS Feeds